Primary Myelofibrosis Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, and others.

DelveInsight's, "Primary Myelofibrosis Pipeline Insight, 2023" report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Primary Myelofibrosis pipeline landscape. It covers the Primary Myelofibrosis pipeline drug profiles, including Primary Myelofibrosis clinical trials and nonclinical stage products. It also covers the Primary Myelofibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Primary Myelofibrosis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Primary Myelofibrosis clinical trials studies, Primary Myelofibrosis NDA approvals (if any), and product development activities comprising the technology, Primary Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from the Primary Myelofibrosis Pipeline Report

• Over 55+ Primary Myelofibrosis companies are evaluating 55+ Primary Myelofibrosis pipeline therapies in various stages of development, and their anticipated acceptance in the Primary Myelofibrosis market would significantly increase market revenue.

• The leading Primary Myelofibrosis Companies include Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, and others.

• Promising Primary Myelofibrosis Pipeline Therapies includes NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat, KER-050, GB 2064, TL-895, TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225, DISC-0974, BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744, JAB-8263, Tasquinimod, Mivebresib, 9-ING-41, Itacitinib, PU-H-71, Selinexor, and others.

• The Primary Myelofibrosis Companies and academics are working to assess challenges and seek opportunities that could influence Primary myelofibrosis R&D. The Primary Myelofibrosis pipeline therapies under development are focused on novel approaches to treat/improve Primary myelofibrosis.

Request a sample and discover the recent breakthroughs happening in the Primary Myelofibrosis Pipeline landscape @ Primary Myelofibrosis Pipeline Outlook Report- https://www.delveinsight.com/report-store/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Myelofibrosis Overview
Primary myelofibrosis (also called chronic idiopathic myelofibrosis, agnogenic myeloid metaplasia) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow known as fibroblasts make these fibers.

Recent Developmental Activities in the Primary Myelofibrosis Treatment Landscape

• In June 2022, Cellenkos announced that the US Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application to initiate a Phase Ib, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.

• In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis.

• In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology's proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.

• In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes.

• In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis.

For further information, refer to the detailed Primary Myelofibrosis Drugs Launch, Primary Myelofibrosis Developmental Activities, and Primary Myelofibrosis News, click here for Primary Myelofibrosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Primary Myelofibrosis Emerging Drugs Profile

• NS 018: Nippon Shinyaku
Ilginatinib (formerly NS 018), a potent inhibitor of Janus kinase 2 (JAK2) enzyme activity and Src-family kinases is being developed by Nippon Shinyaku.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis.

• KRT-232: Kartos Therapeutics
Navtemadlin (KRT-232), is a novel, potent and selective oral MDM2 inhibitor. The MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients with Myelofibrosis (MF), Polycythemia Vera (PV), Acute Myeloid Leukemia (AML), and Merkel Cell Carcinoma (MCC).Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis.

• TP 3654: Sumitomo Pharma Oncology
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of apoptosis. Currently, the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Primary Myelofibrosis.

Primary Myelofibrosis Pipeline Segmentation

Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Primary Myelofibrosis Pipeline Therapeutics Assessment
There are approx. 55+ key companies which are developing the therapies for Primary myelofibrosis. The companies which have their Primary myelofibrosis drug candidates in the most advanced stage, i.e. Phase II/III include, Kartos Therapeutics.

Find out more about the Primary Myelofibrosis Pipeline Segmentation, Therapeutics Assessment, and Primary Myelofibrosis Emerging Drugs @ Primary Myelofibrosis Treatment Landscape- https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Primary Myelofibrosis Pipeline Report

• Coverage- Global

• Primary Myelofibrosis Companies- Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, and others.
• Primary Myelofibrosis Pipeline Therapies- NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat, KER-050, GB 2064, TL-895, TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225, DISC-0974, BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744, JAB-8263, Tasquinimod, Mivebresib, 9-ING-41, Itacitinib, PU-H-71, Selinexor, and others

• Primary Myelofibrosis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Primary Myelofibrosis Pipeline Companies and Therapies, click here @ Primary Myelofibrosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Primary myelofibrosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Primary myelofibrosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase II/III)
8. KRT-232: Kartos Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. NS 018: Nippon Shinyaku
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Primary myelofibrosis Key Companies
21. Primary myelofibrosis Key Products
22. Primary myelofibrosis- Unmet Needs
23. Primary myelofibrosis- Market Drivers and Barriers
24. Primary myelofibrosis- Future Perspectives and Conclusion
25. Primary myelofibrosis Analyst Views
26. Primary myelofibrosis Key Companies
27. Appendix

Got Queries? Find out the related information on Primary Myelofibrosis Mergers and acquisitions, Primary Myelofibrosis Licensing Activities @ Primary Myelofibrosis Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/primary-myelofibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.